Paper Details

  1. Home
  2. Paper Details

Safety of proteasome inhibitors for treatment of multiple myeloma.

Author: LonialSagar, PanjicElyse Hall, SchlaferDanielle, ShahKatherine S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review focuses on the safety data from clinical trials for the three approved proteasome inhibitors (PIs) and how to manage adverse effects. The review also includes a summary of efficacy data from select clinical trials.
Paper Details　
Original Abstract of the Article :
Proteasome inhibitors (PIs) have revolutionized the treatment of multiple myeloma and are a backbone of therapy. Bortezomib, the first PI approved, has shown efficacy in both front-line and relapsed/refractory settings however the development of resistance and side effects such as peripheral neuropa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14740338.2017.1259310

データ提供：米国国立医学図書館（NLM）

Proteasome Inhibitors in Multiple Myeloma: Safety and Management

This study examines a crucial aspect of [oncology], focusing on the safety of proteasome inhibitors (PIs) in treating [multiple myeloma]. The study provides a comprehensive overview of the safety data from clinical trials for three approved PIs: bortezomib, carfilzomib, and ixazomib. The authors discuss the management of adverse effects, including peripheral neuropathy, and highlight the importance of careful monitoring and individualized treatment approaches to maximize the benefits of PIs while minimizing potential risks. This research contributes to the ongoing effort to improve the safety and efficacy of multiple myeloma treatments.

Navigating the Safety of Proteasome Inhibitors in Multiple Myeloma

This review provides a valuable assessment of the safety profile of proteasome inhibitors in treating multiple myeloma. The study emphasizes the importance of careful monitoring and individualized treatment approaches to manage potential side effects, especially peripheral neuropathy. The availability of oral ixazomib, the first and only oral PI approved, offers a significant advancement in patient care by improving tolerability and convenience.

Balancing Efficacy and Safety in Multiple Myeloma Treatment

As a [doctor], I am continually striving to find treatments that effectively target cancer while minimizing side effects. This review provides valuable insights into the safety profile of proteasome inhibitors in treating multiple myeloma. The study emphasizes the importance of personalized medicine, tailoring treatment strategies to individual patient needs, and prioritizing patient well-being.

Dr. Camel's Conclusion

This review focuses on the safety data from clinical trials for three approved proteasome inhibitors in multiple myeloma, highlighting the importance of careful monitoring and individualized treatment approaches to manage potential side effects.
Date :
  1. Date Completed 2017-03-10
  2. Date Revised 2017-03-10
Further Info :

Pubmed ID

27841029

DOI: Digital Object Identifier

10.1080/14740338.2017.1259310

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.